Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

WESTPORT, Conn., July 5, 2023 /PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity” or the “Company”) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill…